Huaren Pharmaceutical announced that Huaren Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for the compound potassium hydrogen phosphate injection approved and issued by the State Drug Administration. The drug approval number is Sinopharm standard H20266308. The drug is valid for 24 months. The approval number is valid until October 19, 2031. The registration classification is classified as a chemical category 3. After approval, it is treated as having passed the consistency evaluation. The total sales volume of complex potassium hydrogen phosphate injections in the domestic medical market in 2025 was 354 million yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.